(Q42990027)

English

The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients

scientific article published on January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

M Raptopoulou

1

1 reference

Europe PubMed Central

12 November 2017

D Tsantoulas

2

1 reference

Europe PubMed Central

12 November 2017

I Vafiadi

3

1 reference

Europe PubMed Central

12 November 2017

I Ketikoglou

4

1 reference

Europe PubMed Central

12 November 2017

E Paraskevas

5

1 reference

Europe PubMed Central

12 November 2017

T Vassiliadis

6

1 reference

Europe PubMed Central

12 November 2017

S Kanatakis

7

1 reference

Europe PubMed Central

12 November 2017

G Hatzis

8

1 reference

Europe PubMed Central

12 November 2017

L Sidiropoulos

9

1 reference

Europe PubMed Central

12 November 2017

E Akriviadis

10

1 reference

Europe PubMed Central

12 November 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

12 November 2017

12

1 reference

Europe PubMed Central

12 November 2017

91-95

1 reference

Europe PubMed Central

12 November 2017

1

1 reference

Europe PubMed Central

12 November 2017

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00549.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2005.00549.X

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42990027&oldid=1975917535"